Arca
Skip to content
Tools
Tools

ACVR2B: Activin receptor type-2B

Transmembrane serine/threonine kinase activin type-2 receptor forming an activin receptor complex with activin type-1 serine/threonine kinase receptors (ACVR1, ACVR1B or ACVR1c).

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on ACVR2B, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 1
  • Protein or peptide 1

Approved1

  • Dibotermin alfa

Phase 31

  • Bimagrumab

Phase 20

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      Dibotermin alfaApprovedLocate Bio LtdProtein or peptideAgonistActivin receptor type-2B agonist8
      BimagrumabPhase 3Eli LillyAntibodyAntagonistActivin receptor type-2B antagonist2

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 10 in all, from ClinicalTrials.gov.
      A Study of Bimagrumab in Participants With HFpEFBimagrumabPhase 2Not yet recruitingEli Lilly and CompanyNov 6, 2026
      A Study of LDGraft In Single Level Lumbar Interbody FusionDibotermin alfaPhase 1 / Phase 2RecruitingLocate Bio LtdOct 5, 2026
      Standard- and Micro-Dose rhBMP-2 for Implant Stability, Marginal Bone Loss, and Postoperative Sequelae: A Double-Blind Randomized Controlled TrialDibotermin alfaNot applicableNot yet recruitingUniversity of BaghdadJul 10, 2026
      Clinical Study of BMP-2 Injectable Hydrogel for Promoting Alveolar Bone RegenerationDibotermin alfaNot applicableNot yet recruitingThe First Affiliated Hospital of Xinxiang Medical CollegeMay 28, 2026
      Effect of Mandibular Drilling Speed on Implant Stability and Osteogenic Potential: A Randomized Clinical TrialDibotermin alfaNot applicableNot yet recruitingCairo UniversityMar 16, 2026
      LDGraft in Single Level Anterior Lumbar Interbody Fusion (ALIF)Dibotermin alfaPhase 1 / Phase 2RecruitingLocate Bio Pty LtdJun 17, 2024
      Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With ObesityBimagrumabPhase 2RecruitingMassachusetts General HospitalJul 6, 2023
      Comparison of Radiographic Fusion Rate and Clinical Outcome of ALIF and XLIF Performed With Either Recombinant Human Bone Morphogenetic Protein-2 or ViviGen®Dibotermin alfaNot applicableRecruitingLindenhofgruppe AGFeb 14, 2022
      Cost Effectiveness in Alveolar Bone Grafting in Patients With Cleft Lip and PalateDibotermin alfaPhase 4RecruitingThe University of Texas Health Science Center, HoustonJan 21, 2020
      Transforaminal Lumbar Interbody Fusion (TLIF)Dibotermin alfaNot applicableActive, not recruitingMedtronic Spinal and BiologicsAug 29, 2019

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Heterotaxia0.74
      • Bone disorder0.37
      • Tibia fracture0.37
      • Spinal fusion0.37
      • Autoimmune disorder of central nervous system0.35
      • Neurodegenerative disease0.33
      • Abnormality of the skeletal system0.29
      • Disorder of pilosebaceous unit0.29
      • Parkinson disease0.28
      • Alzheimer disease0.28
      • Lysosomal storage disease0.28

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5466, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q13705, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.